A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.
Kevin Kalinsky(Emory University), Dawn L. Hershman(Columbia University), Sonya Reid(Vanderbilt University), Amelia Zelnak(Northside Hospital), Prabhjot S. Mundi(Columbia University Irving Medical Center), Erica Stringer-Reasor(University of Alabama at Birmingham), Kari B. Wisinski(University of Wisconsin Carbone Cancer Center), Ruth O’Regan(University of Wisconsin Carbone Cancer Center), Melissa Accordino(Columbia University), Meghna S. Trivedi(Columbia University), Amy Tiersten(Icahn School of Medicine at Mount Sinai), Codruța Chiuzan(Northwell Health), Katherine D. Crew, William J. Gradishar(Northwestern University), Yelena Novik(NYU Langone Health), George Raptis(Northwell Health), Lea Baer(State University of New York), Eleni Andreopoulou(Cornell University), Sun Young Oh(Montefiore Medical Center), Anne O’Dea(University of Kansas Medical Center)
Cited by 73
Related Papers
Epidemiology of gastric cancer
|World Journal of Gastroenterology|2006|2.1k
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.6k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2014|1.2k
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
|Journal of Clinical Oncology|2021|991